

#1310
ms
04/16/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lustig et al.

Serial No. 09/163,713

Filed: September 30, 1998

For: *Nuclear Hormone Receptor Drug Screens*

Group Art Unit: 1646

Examiner: Pak, M.

Attorney Docket No. T97-012-1

CERTIFICATE OF TRANSMISSION

I hereby certify that this corr is being transmitted by facsimile to the Comm for Patents at (703) 308-4242 on April 12, 2001.

Signature

Richard Aron Osman

FAX RECEIVED

APR 13 2001

GROUP 1600

OFFICIAL

RESPONSEThe Commissioner for Patents
Washington, DC 20231

Dear Examiner Pak:

Thank you for the Final Action mailed Jan 17, 2000. Please enter these amendments:

IN THE CLAIMS

32. (Amended) An in vitro assay method for modulators of a nuclear hormone receptor binding function, comprising steps:

forming an in vitro mixture comprising a first nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the first receptor, wherein the sensor consists of a peptide comprising the sequence $L_1X_1X_2L_2L_3$ (SEQ ID NO:18) covalently coupled to a detectable label, wherein L_1 - L_3 are independently selected from hydrophobic amino acids and X_1 - X_2 are independently selected from any amino acid and wherein the peptide provides direct, in vitro ligand-dependent binding to the first receptor and is 24 or fewer residues in length;

measuring an agent-biased binding of the sensor to the first receptor by detecting immobilized first receptor-sensor complexes;

comparing the agent-biased binding with a corresponding unbiased binding of the sensor to the first receptor;

04/16/2001 MBRGWN 00000001 190750 09163713 01 FC:215 55.00

Adjustment date: 10/23/2001
04/16/2001 MBRGWN 00000001 190750 09163713 01 FC:215 55.00